A detailed history of Ubs Oconnor LLC transactions in Schrodinger, Inc. stock. As of the latest transaction made, Ubs Oconnor LLC holds 30,000 shares of SDGR stock, worth $639,900. This represents 0.04% of its overall portfolio holdings.

Number of Shares
30,000
Holding current value
$639,900
% of portfolio
0.04%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$18.05 - $24.02 $149,905 - $199,486
8,305 Added 41.5%
28,316 $525,000
Q2 2024

Aug 14, 2024

SELL
$18.65 - $28.5 $109,941 - $168,007
-5,895 Reduced 22.76%
20,011 $387,000
Q1 2024

May 15, 2024

SELL
$24.74 - $35.13 $116,921 - $166,024
-4,726 Reduced 15.43%
25,906 $699,000
Q4 2023

Feb 14, 2024

SELL
$21.62 - $37.21 $109,570 - $188,580
-5,068 Reduced 14.2%
30,632 $1.1 Million
Q3 2023

Nov 14, 2023

BUY
$27.34 - $55.37 $587,810 - $1.19 Million
21,500 Added 151.41%
35,700 $1.01 Million
Q2 2023

Aug 14, 2023

BUY
$26.1 - $49.92 $370,620 - $708,864
14,200 New
14,200 $709 Million
Q1 2023

May 15, 2023

SELL
$18.09 - $27.61 $1.21 Million - $1.85 Million
-67,000 Reduced 78.75%
18,081 $476,000
Q4 2022

Feb 14, 2023

BUY
$16.24 - $26.38 $89,872 - $145,986
5,534 Added 6.96%
85,081 $0
Q3 2022

Nov 14, 2022

BUY
$23.95 - $34.71 $119,750 - $173,550
5,000 Added 6.71%
79,547 $1.99 Billion
Q2 2022

Aug 12, 2022

BUY
$21.39 - $35.9 $952,860 - $1.6 Million
44,547 Added 148.49%
74,547 $1.97 Million
Q1 2022

May 16, 2022

BUY
$24.84 - $36.12 $149,040 - $216,719
6,000 Added 25.0%
30,000 $1.02 Million
Q3 2020

Nov 12, 2020

BUY
$46.87 - $93.33 $421,830 - $839,970
9,000 Added 60.0%
24,000 $1.14 Million
Q1 2020

May 15, 2020

BUY
$26.6 - $52.99 $399,000 - $794,850
15,000 New
15,000 $646,000

Others Institutions Holding SDGR

About Schrodinger, Inc.


  • Ticker SDGR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Health Information Services
  • Shares Outstandng 62,028,400
  • Market Cap $1.32B
  • Description
  • Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences i...
More about SDGR
Track This Portfolio

Track Ubs Oconnor LLC Portfolio

Follow Ubs Oconnor LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Oconnor LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Oconnor LLC with notifications on news.